SINOVAC BIOTECH LTD (SVA) Form 6-K — Jun 5, 2026
Sinovac Biotech reported full year 2025 sales of $386.0 million, an increase from $361.4 million in the prior year, driven by a 93.9% surge in overseas sales to $124.8 million. Despite revenue growth, the company swung to a net loss of $59.7 million, or $0.83 per share, compared to net income of $90.9 million in the prior year, primarily due to significant non-cash impairment charges. The company recorded total impairment losses of $202.8 million across property, plant, equipment, in-process R&D, and goodwill, citing indicators such as fierce competition and drops in lease market prices in Hangzhou and Beijing.
Key figures
- Revenue
- 386000000
- Cash Position
- 1.2 billion
- Overseas sales
- 124800000
- Total impairment loss
- 202800000
- Cash used in financing
- 3434706000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.